Nuformix plc (LON:NFX – Get Free Report) dropped 15% during trading on Tuesday. The company traded as low as GBX 0.09 and last traded at GBX 0.10. Approximately 36,537,223 shares traded hands during mid-day trading, an increase of 26% from the average daily volume of 29,015,109 shares. The stock had previously closed at GBX 0.11.
Nuformix Trading Down 4.5%
The company has a market capitalization of £2.74 million, a PE ratio of -3.58 and a beta of 1.53. The business’s 50-day simple moving average is GBX 0.14 and its 200-day simple moving average is GBX 0.16.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
See Also
- Five stocks we like better than Nuformix
- AI Spending Is Surging—But Which Stocks Still Win if It Slows Down?
- Are RTX Corporation and Northrop Grumman Ready to Break Out?
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
